Louisiana sees first ENCELTO gene therapy procedure at AVALA Hospital

KEY TAKEAWAYS:

Louisiana’s first ENCELTO procedure performed at AVALA Hospital .

Gene therapy delivers rhCNTF directly to the retina for MacTel .

Outpatient surgery performed by Dr. Stanislav Zhuk of Retina Associates.

Treatment offers first approved option to slow or prevent vision loss.

AVALA Hospital, in partnership with Retina Associates New Orleans , has successfully performed Louisiana’s first ENCELTO procedure, a cell-based gene therapy for adults with macular telangiectasia type 2 (MacTel).

The outpatient surgery was performed by Dr. Stanislav Zhuk, marking an advancement in retinal care and personalized medicine in the state.

ENCELTO, developed by Neurotech Pharmaceuticals, delivers recombinant human ciliary neurotrophic factor (rhCNTF) directly to the retina